Compare Ginkgo Bioworks Holdings Inc (DNA) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.91 (market cap $772.39M), while First Trust NASDAQ 100 Technology Index Fund trades at $333 (market cap $4.15B). The key difference: First Trust NASDAQ 100 Technology Index Fund is far larger — about 5.4× Ginkgo Bioworks Holdings Inc's market cap, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| DNA | QTEC | |
|---|---|---|
Market Cap | $772.39M | $4.15B |
Volume | 6,453,273 | 278,646 |
Sector | Health | Broad Market / Factor |
52-Week High | $15.83 | $340.28 |
52-Week Low | $5.48 | $207.03 |
Typical Hold Time | 7 Days | 40 Days |
Enterprise Value | $874.34M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
QTEC trades at $335.82, down 1.31% today, with a bullish technical signal from moving averages but bearish oscillators. The ETF provides equal-weighted exposure to NASDAQ-100 technology stocks, offering diversification across software and hardware sectors. Recent analysis highlights software industry undervaluation relative to historical averages, positioning QTEC as a liquid alternative to similar funds.
The outlook remains cautiously optimistic given technology sector growth potential, though overbought RSI levels suggest near-term consolidation. Key risks include sector volatility and macroeconomic pressures on tech valuations, while institutional interest supports long-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
